Zenaxis, an accelerator and TIPS operator, has invested in Orand Bio (CEO Dong-Geun Han), a bio company that researches and develops convergence medical products including tissue engineering products and pharmaceuticals based on advanced biomaterials.
TIPS (Tech Incubator Program for Startups) is a program in which the Ministry of SMEs and Startups and private investment companies collaborate to discover startups with technological prowess and innovative items that will lead the global market and support their R&D (research and development) and commercialization.
Orand Bio possesses biomaterial molding and processing technology, bioactive particle technology, anti-inflammatory technology for biodegradable polymers, biofunctional and active support, and tissue regeneration technology, and is developing medical devices and tissue engineering products related to kidneys, knees, bones, teeth, and regenerative tissues and organs.
The flagship product, 'CharmRenal', a kidney function recovery support, can restore kidney function, which has decreased by about 15%, to 30-50%, unlike other companies' treatments that cannot restore kidney function to normal. It is being developed with the goal of becoming the World's First as it can prevent and treat patients who become dialysis patients and chronic renal failure patients. In addition, the osteoarthritis treatment 'CharmCarti' aims to treat stage 3, which is severe, as well as stage 2, which is mild, among the 4 stages of degenerative arthritis progression.
'CharmCarti' is currently under development with the goal of securing Best-in-class status by reducing friction in the knee joint, minimizing additional damage, and inducing cartilage regeneration by reducing pain and inflammation.
In addition to this, Orland Bio is developing medical devices such as the highly functional bone graft material 'CharmOss', the periodontal tissue regeneration inducer 'CharmGuide', and various tissue engineering products such as the regenerative kidney 'CharmKidney', the regenerative articular cartilage 'CharmChon', the regenerative nerve 'CharmNerve', and the regenerative bone 'CharmBone'.
In April 2025, Orand Bio developed a 'stem cell-containing anti-inflammatory and antioxidant sponge-type support' containing PDRN and melatonin. The support is characterized by creating an environment similar to ovarian tissue, promoting blood vessel creation, suppressing active oxygen, and effectively inducing ovarian tissue recovery. This technology produced significant results in normalizing ovarian function and female hormone levels, and successful childbirth in a mouse model that reached menopause due to cancer treatment. The results of the study were published in Advanced Healthcare Materials (AHM) on April 14, 2025.
In 2026, Orand Bio will begin non-clinical trials for its kidney function recovery supporter, CharmRenal, and its osteoarthritis treatment, CharmCarti, and aims to establish a production system for equivalent products (GMP OEM) of periodontal tissue regeneration inducers, secure major sales channels, and expand government project orders. In 2027, it plans to complete the equivalence evaluation and product development of synthetic bone grafts (CharmOss-S), xenograft bone grafts (CharmOss-B), and periodontal tissue regeneration inducers (CharmGuide), obtain approval from the Ministry of Food and Drug Safety, and launch them in the domestic market. In addition, clinical trials of new periodontal tissue regeneration inducers are scheduled, and it plans to further strengthen its market leadership in the field of tissue regeneration medical devices.
Zenaxis, which made this investment, evaluated that “Orand Bio has patents in the fields of biomaterials, medical devices, and tissue regeneration, as well as a track record of publishing SCIE-level papers,” and that “Based on a clinical advisory network comprised of medical staff from major university hospitals, it has high growth potential in the fields of medical devices and tissue engineering products.”
- See more related articles
You must be logged in to post a comment.